Observational studyOncology reports2021
MicroRNA‑485‑5p suppresses the progression of esophageal squamous cell carcinoma by targeting flotillin‑1 and inhibits the epithelial‑mesenchymal transition.
Observational study in Oncology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 14 citations in OpenAlex.
- Luteolin suppresses cell migration and invasion via targeting miR-6809-5p/FLOT1/FAK and eliciting EMT in hepatocellular carcinoma.Translational oncology · 2025Article
- LINC00704 boosts the immunologic escape of colorectal cancer cells by upregulating TLR4 by binding with miR- 203a- 3p.European journal of medical research · 2025Article
- CMSP exerts anti-tumor effects on small cell lung cancer cells by inducing mitochondrial dysfunction and ferroptosis.Open medicine (Warsaw, Poland) · 2025Article
- Non‑coding RNA: A promising diagnostic biomarker and therapeutic target for esophageal squamous cell carcinoma (Review).Oncology letters · 2024Review
- MicroRNAs: A novel signature in the metastasis of esophageal squamous cell carcinoma.World journal of gastroenterology · 2024Review
- MicroRNAs Associated with Androgen Receptor and Metastasis in Triple-Negative Breast Cancer.Cancers · 2024Article
- Circ_0003855 involvement of esophageal cancer progression through miR-622/FLOT1.Oncology research · 2024Article
- LncRNA PKMYT1AR promotes cancer stem cell maintenance in non-small cell lung cancer via activating Wnt signaling pathway.Molecular cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As esophageal squamous cell carcinoma (ESCC) is one of the most frequently diagnosed cancers in Asia, it is crucial to uncover its underlying molecular mechanisms that support its development and progression. Several articles have reported that microRNA (miR)‑485‑5p inhibits the malignant phenotype in a number of cancer types, such as lung, gastric and breast cancer, but to the best of our knowledge, its function in ESCC has not been studied in depth until the present study. It is of great significance to probe the regulatory action and underlying mechanism of miR‑485‑5p in ESCC. In brief, this study identified that miR‑485‑5p expression in ESCC tissues was significantly lower than that in normal tissues. The decrease in miR‑485‑5p expression was associated with a larger tumour size and poor histology and stage. The expression of miR‑485‑5p was relatively high in Eca 109 and TE‑1 cells, but relatively low in KYSE 30. The overexpression of miR‑485‑5p inhibited cell proliferation, migration and invasion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.